Ghina Tsurayya

Ms. Ghina Tsurayya

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2024 in JMIR Medical Education
Verified
Journal Article
Open access
MMMahsusi Mahsusi
Mahsusi Mahsusi
SHSyihaabul Hudaa
Syihaabul Hudaa
NNNuryani Nuryani
Nuryani Nuryani
MFMustofa Fahmi
Mustofa Fahmi
GTGhina Tsurayya
Ghina Tsurayya
Muhammad IqhrammullahMuhammad Iqhrammullah
Muhammad Iqhrammullah
Background: During health crises such as the COVID-19 pandemic, shortages of health care workers often occur. Recruiting students as volunteers could be an option, but it is uncertain whether the idea is well-accepted. Objective: This study aims to estimate the global rate of willingness to volunteer among medical and health students in response to the COVID-19 pandemic. Methods: A systematic search was conducted on PubMed, Embase, Scopus, and Google Scholar for studies reporting the number of health students willing to volunteer during COVID-19 from 2019 to November 17, 2023. The meta-analysis was performed using a restricted maximum-likelihood model with logit transformation. Results: A total of 21 studies involving 26,056 health students were included in the meta-analysis. The pooled estimate of the willingness-to-volunteer rate among health students across multiple countries was 66.13%, with an I2 of 98.99% and P value of heterogeneity (P-Het)<.001. Removing a study with the highest influence led to the rate being 64.34%. Our stratified analyses indicated that those with older age, being first-year students, and being female were more willing to volunteer (P<.001). From highest to lowest, the rates were 77.38%, 77.03%, 65.48%, 64.11%, 62.71%, and 55.23% in Africa, Western Europe, East and Southeast Asia, Middle East, and Eastern Europe, respectively. Because of the high heterogeneity, the evidence from this study has moderate strength. Conclusions: The majority of students are willing to volunteer during COVID-19, suggesting that volunteer recruitment is well-accepted.

9 February 2024 in Children
Verified
Journal Article
Open access
PDF file
GTGhina Tsurayya
Ghina Tsurayya
CNCut Alifiya Nazhifah
Cut Alifiya Nazhifah
MPM. Rahmat Pirwanja
M. Rahmat Pirwanja
PZPutri Oktaviani Zulfa
Putri Oktaviani Zulfa
MTMuhammad Raihan Ramadhan Tatroman
Muhammad Raihan Ramadhan Tatroman
Muhammad IqhrammullahMuhammad Iqhrammullah
Muhammad Iqhrammullah
Growth hormone treatment has effectively restored normal growth in children with growth hormone deficiency (GHD); however, it poses challenges in compliance with a daily growth hormone injection regimen, leading to low adherence and persistence rates. Once-weekly Somapacitan is a potential alternative for treating children with GHD. This study aimed to evaluate the efficacy, safety, and adherence of once-weekly subcutaneous Somapacitan compared to daily growth hormone injection in prepubertal children with GHD. A search for the published records was carried out on 17 October 2023 utilizing the searching feature available on PubMed, Embase, and Scopus. Primary study outcomes included (1) efficacy, measured by height velocity (HV), standard deviation score (SDs), height SDs, insulin-like growth factor-SDs (IGF-I SDs), and bone age vs. chronological age ratio (BA vs. CA); (2) safety, assessed through adverse events and injection site reactions; and (3) adherence, determined by the percentage of the sample completing treatments. Secondary outcomes evaluated disease burden scores, divided into three subgroup domains: emotional well-being, physical functional, and social well-being scores. We retrieved 6 studies that were eligible for the systematic review (417 versus 186 for intervention and control, respectively). Only 2 of the total included studies were eligible for pooled analysis (175 versus 82 for intervention and control, respectively). The efficacy profile of Somapacitan was similar to daily growth hormones, indicated by HV (mean difference (MD = 0.04; p = 0.96), HV SDs (MD = −0.71; p = 0.09), height SDs (MD = 0.11; p = 0.69), IGF-I SDs (MD = 0.06; p = 0.70), and CA vs. BA (MD = 0.67; p = 0.70)), demonstrated similar and non-inferior outcomes. Treatment adherence is 3 times higher in the Somapacitan group as compared to control (OR = 3.02; p = 0.03) with adherence rates reaching 95% and 88% for Somapacitan and Norditropin®, respectively. The disease burden measurement is similar in Somapacitan and daily growth hormones (MD = −0.62; p = 0.83), as indicated by the Growth Hormone Deficiency–Child Impact Measure. In almost all outcomes, the level of confidence is strong. The confidence level in the data is generally strong, but for CA vs. BA and the subgroup of severe adverse events with heterogeneity >50%, the confidence level is moderate. Although the efficacy and safety profiles of Somapacitan were found to be similar to those of daily growth hormones, a reduced frequency of once-weekly Somapacitan injections led to increased adherence. PROSPERO registration: CRD42023473209.


31 December 2023 in Narra X
Verified
Journal Article
Open access
PDF file
GTGhina Tsurayya
Ghina Tsurayya
TDTeuku F. Duta
Teuku F. Duta
MNMuhammad A. Naufal
Muhammad A. Naufal
MAMeulu Alina
Meulu Alina
CIChinwe C. Isitua
Chinwe C. Isitua
EOErnest C. Ohanu
Ernest C. Ohanu
The aim of this study was to evaluate the efficacy, safety, adherence, and acceptance of exergame in improving the quality of life (QoL) among elderly patients with neurodegenerative diseases. A systematic search was conducted in PubMed, Embase and Scopus for relevant studies up to 16 March 2023. Quality of the included studies were assessed using Cochrane’s Risk of Bias tool version 2.0. Meta-analysis using a random effect was conducted on outcomes reported at least by two studies to calculate the standard mean difference (SMD) and its 95% confidence interval (CI). The difference of influence between exergame and conventional therapy was judged based on Z- and p-values. Heterogeneity was determined by I2 score. As many as 15 studies were included (n=466 participants) published between 2013–2023. Nine studies had ‘high quality’ five studies had ‘some concerns’, and one had ‘high risk’. Results from meta-analyses suggests that the exergame does significantly not improve the QoL among patients with Parkinson’s diseases. Similarly, no statistically significant difference (p>0.05) of QoL improvement among Alzheimer’s disease patients receiving exergame intervention. No adverse effects were reported to be associated with the intervention, and in fact, the patients experienced reduced fatigue and fear of falling. Patients in intervention group showed high acceptance and adherence to the therapy, which could be attributed to exergame being enjoyable, easy-to-use, and motivational. In conclusion, despite exergame being highly acceptable and relatively safe, the intervention does not improve the QoL of the elderly patients.

21 May 2024 in Narra X
Verified
Journal Article
Open access
PDF file
TDTeuku F. Duta
Teuku F. Duta
PZPutri O. Zulfa
Putri O. Zulfa
MAMeulu Alina
Meulu Alina
NHNajlaika Henira
Najlaika Henira
GTGhina Tsurayya
Ghina Tsurayya
Yogesh AcharyaYogesh Acharya
Yogesh Acharya
Acetazolamide, one of the carbonic anhydrase inhibitors, has been known to improve the efficacy of diuretic therapy in patients with in congestion heart failure. The aim this study was to investigate the effectiveness of acetazolamide when combined with loop diuretics in ameliorating diuresis and natriuresis in congestive heart failure using systematic review and meta-analysis. Randomized controlled trials (RCTs) and cohort studies were searched on PubMed, Scopus, and Embase on March 7, 2023, by using combinations of ‘acetazolamide’, ‘heart failure’ and along with their respective synonyms. The protocol had been registered on PROSPERO (CRD42023409864). The studies must investigate the effect of oral acetazolamide as the add-on to loop diuretic therapy to be included. Successful decongestion, natriuresis, and diuresis were set as the primary outcomes. The quality of the included studies was assessed using the Cochrane risk-of-bias tool for RCTs and Newcastle Ottawa Scale for observational studies. We identified 1176 titles in the initial search, and further reduced to five studies (three RCTs and two cohort studies) after in-depth screening. A total of 625 patients were recruited in the included studies published from 2015 to 2022. Results from meta-analysis revealed that acetazolamide and loop diuretics combination therapy ameliorated natriuresis (n=4; standardized means difference (SMD): 0.65; 95%CI: 0.07–1.24; p=0.03) and diuresis (n=2; SMD: 0.29; 95%CI: 0.12–0.46; p=0.0009) when compared to loop diuretics alone. Acetazolamide and loop diuretics combinatorial therapy is efficacious in alleviating congestion in heart failure patients.

31 December 2023 in Narra X
Verified
Journal Article
Open access
PDF file
GTGhina Tsurayya
Ghina Tsurayya
CNCut A. Nazhifah
Cut A. Nazhifah
MPMuhammad R. Pirwanja
Muhammad R. Pirwanja
YLYohannes K. Lemu
Yohannes K. Lemu
In managing severe acute malnutrition (SAM) among children, the World Health Organization has endorsed the use of ready-to-use therapeutic foods (RUTF), especially the peanut and milk-based (PM-RUTF), which has been proven for its efficacy. Unfortunately, the distribution of PM-RUTF is challenged by high financial cost and reliance on imports for milk and peanuts. Researchers explore the Soy-Maize-Sorghum (SMS)-RUTF as the alternative, in which the formulation has two types; milk-free soya-maize-sorghum (FSMS)-RUTF and low milk content SMS (MSMS)-RUTF. The aim of this study was to evaluate the efficacy, safety, and acceptance of SMS-RUTFs in the management of SAM among children as compared with PM-RUTF. Eligible studies were searched through PubMed, Scopus, and Embase up to July 14, 2023. Studies reporting the effects of SMS-RUTF, FSMS-RUTF, or MSMS-RUTF intake on SAM with PM-RUTF as the control were considered eligible. The included randomized controlled trials were then assessed for the risk of bias using Cochrane Risk of Bias 2.0. Odds Ratio (OR) and mean difference (MD) were calculated using a random-effects meta-analysis. The analysis focused on investigating the recovery, mortality, weight gain, and hemoglobin levels. Five randomized controlled trials involving a total of 5,513 children were incorporated in this review. Of which, four studies were included in the statistical analysis. Those receiving SMS-RUTF was 0.77 times less likely to recover from SAM as compared to control (95% CI: 0.66–0.90, p<0.01). The SMS-RUTF group had 1 kg lower weight gain as compared to control (95% CI: -1.25–0.75, p<0.01). However, the SMS-RUTF group had significantly higher increase of hemoglobin level than control (MD: 0.80 g/dL [95% CI: 0.68–0.93], p<0.01). Adverse effects were observed similar in both SMS-RUFT and control groups. SMS-RUFT received low acceptance from the participants suspected to be caused by poor packaging. In conclusion, SMS-RUTF is less effective than PM-RUTF in managing SAM among children but can be used to improve anemia as indicated by increased hemoglobin levels.